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Staphylococcus aureus is an opportunistic human pathogen that has the ability to cause both health care -
associated and community-acquired infections [1]. It has been identified as one of the ‘high priority 
pathogen’ by the World Health Organization (WHO) [5]  The infections were once, easily treated with antibiotics 
before resistance against beta-lactams (eg. Methicillin) and glycopeptides (eg. Vancomycin) began to emerge 
over the years and caused an increase in mortality and morbidity rates in patients infected with S. aureus        
[2,3]. This has led to an increased interest in the exploration of the use of bacteriophage as an alternative 
approach way to combat MRSA  because a bacteriophage has bacteriolytic mechanism independent from 
those of any known antibiotics [5]. The availability of a virulent and broad spectrum bacteriophage against 
MRSA may significantly reduce the overall biorisk as it acts as an effective treatment in case of exposure.  
Objectives 
To evaluate the antibacterial property of  
Staphyphage ɸNuSA-10 against Methicillin 
Resistant (MRSA) and Methicillin 






























ϕNuSA-10, is a 
Myovirus-like Staphyphage  
isolated from the 
sewage against 
Staphylococcus 
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ɸNuSA-10 kills ~92% 
of both MRSA and 
MSSA 
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The effectiveness of ɸNuSA-10 against MRSA and MSSA reduces the 
biorisk of MRSA research as it acts as a potential alternative yet effective 
antimicrobial  against MRSA and potentially VRSA in the absence of 
effective antibiotics. Nevertheless, complete characterization, risk 
assessment and purification of ɸNuSA-10 are required before being used 











CLEAR ZONE: TURBID ZONE: NO ZONE:
MRSA [n=25] 92.00 4.00 4.00























The lytic efficacy of ɸNuSA-10 on MRSA 
and MSSA
